The diabetes medication Ozempic, a blockbuster drug from Novo Nordisk, has become a symbol of healthcare inequality. While Canadians have access to a cheaper generic version, Americans face soaring prices and limited availability. The UK’s NHS pricing model is now being held up as a fairer alternative, but the situation exposes deeper systemic flaws across the Atlantic.
In Canada, the arrival of a generic semaglutide (the active ingredient in Ozempic) has slashed costs by up to 40%. This is due to Canada’s Patented Medicine Prices Review Board, which caps drug prices and encourages competition. For American patients, however, the story is different. The US lacks similar price controls, leaving millions uninsured or underinsured. A month’s supply of Ozempic can cost over $1,000 in the US, compared to around $200 in Canada.
The UK’s NHS, meanwhile, negotiates directly with pharmaceutical companies and uses a cost-effectiveness threshold. This has kept prices for Ozempic and other GLP-1 drugs relatively low, but not without controversy. The NHS’s recent decision to restrict access to Wegovy (a higher-dose version) due to supply shortages highlights the tension between affordability and availability.
The core issue is patent law and market exclusivity. In Canada, the patent on semaglutide expired, allowing generics. In the US, Novo Nordisk has used secondary patents to extend its monopoly, a practice known as “evergreening.” This keeps prices high and limits competition. The UK’s system, while not perfect, balances innovation with public health: companies get a fair return, but the NHS has leverage to keep prices in check.
For patients, this means a lottery of geography. A Canadian diabetic pays a fraction of what an American does for the same drug. The UK patient pays less than both, but faces rationing. The question is whether the US can learn from its northern neighbour and the UK, or whether patent reform is needed.
Critics argue that cheaper generics discourage innovation. But the data suggests otherwise: generics typically appear after years of monopoly, and companies still make billions. The real challenge is ensuring access without stifling future cures. One could argue that the American system actually stifles innovation by prioritising profit over unmet need.
Technology offers a glimmer of hope. Blockchain-based supply chains could improve drug tracking and reduce counterfeit risks in generics. AI-driven drug discovery might lower R&D costs, making lower prices sustainable. But these are long-term solutions. For now, the disparity in Ozempic access is a stark reminder that healthcare is a human right, not a commodity.
As the world watches, the UK’s NHS model may emerge as a template for a third way. But until patent laws change and political will aligns, Canadians and Britons will continue to live in a more equitable pharmaceutical landscape than their American cousins.
